Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

108Citations
Citations of this article
180Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

If there is a great new hope in the treatment of cancer, the immune system is it. Innate and adaptive immunity either promote or attenuate tumorigenesis and so can have opposing effects on the therapeutic outcome. Originally described as potent antivirals, Type-I interferons (IFNs) were quickly recognized as central coordinators of tumor-immune system interactions. Type-I-IFNs are produced by, and act on, both tumor and immune cells being either host-protecting or tumor-promoting. Here, we discuss Type-I-IFNs in infectious and cancer diseases highlighting their dichotomous role and raising the importance to deeply understand the underlying mechanisms so to reshape the way we can exploit Type-I-IFNs therapeutically.

Cite

CITATION STYLE

APA

Musella, M., Manic, G., De Maria, R., Vitale, I., & Sistigu, A. (2017). Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. OncoImmunology, 6(5). https://doi.org/10.1080/2162402X.2017.1314424

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free